Glycaemic Efficacy and Safety of Linagliptin compared to Basal ‐Bolus Insulin Regimen in Patients with Type 2 Diabetes Undergoing Non‐Cardiac Surgery: A Multicenter Randomized Clinical Trial

ConclusionsIn patients with T2D undergoing non ‐cardiac surgery presenting with mild to moderate hyperglycaemia (BG<11.1 mmol/L), daily linagliptin is a safe and effective alternative to multi ‐dose insulin therapy resulting in similar glucose control with lower hypoglycaemia.This article is protected by copyright. All rights reserved.

Source: Diabetes, Obesity and Metabolism - November 20, 2018 Category: Endocrinology Authors: Priyathama Vellanki, Neda Rasouli, David Baldwin, Sara Alexanian, Isabel Anzola, Maria Urrutia, Saumeth Cardona, Limin Peng, Francisco J. Pasquel, Guillermo E. Umpierrez, Linagliptin Inpatient Research Group Tags: ORIGINAL ARTICLE Source Type: research